Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism

Terrence Riehl, Steven Cohn, Teresa Tessner, Suzanne Schloemann, William F. Stenson

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Background and Aims: The bone marrow and the intestine are the major sites of radiation-induced injury. The cellular response to radiation injury in the intestine or bone marrow can be modulated by agents given before irradiation. Lipopolysaccharide is known to be radioprotective in the bone marrow, but its effect on the intestine is not known. We sought to determine if lipopolysaccharide is radioprotective in the intestine and, if so, to determine the mechanism of its radioprotective effects. Methods: Mice were treated with parenteral lipopolysaccharide or vehicle and then irradiated (14 Gy total body irradiation in a cesium irradiator). The number of surviving intestinal crypts was assessed 3.5 days after irradiation using a clonogenic assay. Results: Parenteral administration of lipopolysaccharide 2-24 hours before irradiation resulted in a 2-fold increase in the number of surviving crypts 3.5 days after irradiation. The radioprotective effects of lipopolysaccharide could be eliminated by coadministration of a selective inhibitor of cyclooxygenase 2. Lipopolysaccharide was radioprotective in wild-type mice but not in mice with a disrupted cyclooxygenase 2. Parenteral administration of lipopolysaccharide resulted in increased production of prostaglandins in the intestine and in the induction of cyclooxygenase 2 expression in subepithelial fibroblasts and in villous, but not crypt, epithelial cells. Conclusions: Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-dependent pathway.

Original languageEnglish (US)
Pages (from-to)1106-1116
Number of pages11
JournalGastroenterology
Volume118
Issue number6
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Prostaglandins
Intestines
Lipopolysaccharides
Radiation Injuries
Bone Marrow
Cyclooxygenase 2
Cesium
Whole-Body Irradiation
Cyclooxygenase 2 Inhibitors
Fibroblasts
Epithelial Cells

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. / Riehl, Terrence; Cohn, Steven; Tessner, Teresa; Schloemann, Suzanne; Stenson, William F.

In: Gastroenterology, Vol. 118, No. 6, 01.01.2000, p. 1106-1116.

Research output: Contribution to journalArticle

Riehl, Terrence ; Cohn, Steven ; Tessner, Teresa ; Schloemann, Suzanne ; Stenson, William F. / Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. In: Gastroenterology. 2000 ; Vol. 118, No. 6. pp. 1106-1116.
@article{63a330d6efd14e1db3cb6ccc99d002d5,
title = "Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism",
abstract = "Background and Aims: The bone marrow and the intestine are the major sites of radiation-induced injury. The cellular response to radiation injury in the intestine or bone marrow can be modulated by agents given before irradiation. Lipopolysaccharide is known to be radioprotective in the bone marrow, but its effect on the intestine is not known. We sought to determine if lipopolysaccharide is radioprotective in the intestine and, if so, to determine the mechanism of its radioprotective effects. Methods: Mice were treated with parenteral lipopolysaccharide or vehicle and then irradiated (14 Gy total body irradiation in a cesium irradiator). The number of surviving intestinal crypts was assessed 3.5 days after irradiation using a clonogenic assay. Results: Parenteral administration of lipopolysaccharide 2-24 hours before irradiation resulted in a 2-fold increase in the number of surviving crypts 3.5 days after irradiation. The radioprotective effects of lipopolysaccharide could be eliminated by coadministration of a selective inhibitor of cyclooxygenase 2. Lipopolysaccharide was radioprotective in wild-type mice but not in mice with a disrupted cyclooxygenase 2. Parenteral administration of lipopolysaccharide resulted in increased production of prostaglandins in the intestine and in the induction of cyclooxygenase 2 expression in subepithelial fibroblasts and in villous, but not crypt, epithelial cells. Conclusions: Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-dependent pathway.",
author = "Terrence Riehl and Steven Cohn and Teresa Tessner and Suzanne Schloemann and Stenson, {William F.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S0016-5085(00)70363-5",
language = "English (US)",
volume = "118",
pages = "1106--1116",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism

AU - Riehl, Terrence

AU - Cohn, Steven

AU - Tessner, Teresa

AU - Schloemann, Suzanne

AU - Stenson, William F.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background and Aims: The bone marrow and the intestine are the major sites of radiation-induced injury. The cellular response to radiation injury in the intestine or bone marrow can be modulated by agents given before irradiation. Lipopolysaccharide is known to be radioprotective in the bone marrow, but its effect on the intestine is not known. We sought to determine if lipopolysaccharide is radioprotective in the intestine and, if so, to determine the mechanism of its radioprotective effects. Methods: Mice were treated with parenteral lipopolysaccharide or vehicle and then irradiated (14 Gy total body irradiation in a cesium irradiator). The number of surviving intestinal crypts was assessed 3.5 days after irradiation using a clonogenic assay. Results: Parenteral administration of lipopolysaccharide 2-24 hours before irradiation resulted in a 2-fold increase in the number of surviving crypts 3.5 days after irradiation. The radioprotective effects of lipopolysaccharide could be eliminated by coadministration of a selective inhibitor of cyclooxygenase 2. Lipopolysaccharide was radioprotective in wild-type mice but not in mice with a disrupted cyclooxygenase 2. Parenteral administration of lipopolysaccharide resulted in increased production of prostaglandins in the intestine and in the induction of cyclooxygenase 2 expression in subepithelial fibroblasts and in villous, but not crypt, epithelial cells. Conclusions: Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-dependent pathway.

AB - Background and Aims: The bone marrow and the intestine are the major sites of radiation-induced injury. The cellular response to radiation injury in the intestine or bone marrow can be modulated by agents given before irradiation. Lipopolysaccharide is known to be radioprotective in the bone marrow, but its effect on the intestine is not known. We sought to determine if lipopolysaccharide is radioprotective in the intestine and, if so, to determine the mechanism of its radioprotective effects. Methods: Mice were treated with parenteral lipopolysaccharide or vehicle and then irradiated (14 Gy total body irradiation in a cesium irradiator). The number of surviving intestinal crypts was assessed 3.5 days after irradiation using a clonogenic assay. Results: Parenteral administration of lipopolysaccharide 2-24 hours before irradiation resulted in a 2-fold increase in the number of surviving crypts 3.5 days after irradiation. The radioprotective effects of lipopolysaccharide could be eliminated by coadministration of a selective inhibitor of cyclooxygenase 2. Lipopolysaccharide was radioprotective in wild-type mice but not in mice with a disrupted cyclooxygenase 2. Parenteral administration of lipopolysaccharide resulted in increased production of prostaglandins in the intestine and in the induction of cyclooxygenase 2 expression in subepithelial fibroblasts and in villous, but not crypt, epithelial cells. Conclusions: Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-dependent pathway.

UR - http://www.scopus.com/inward/record.url?scp=0034040576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034040576&partnerID=8YFLogxK

U2 - 10.1016/S0016-5085(00)70363-5

DO - 10.1016/S0016-5085(00)70363-5

M3 - Article

VL - 118

SP - 1106

EP - 1116

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 6

ER -